Sunday, November 24, 2024 11/24/2024

Development of novel malaria pre-erythrocytic vaccine antigens targeting Plasmodium sporozoite liver infection

Award Number: R21AI166451
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Previously, using a phage peptide display library, our group has identified Plasmodium parasite ligands and corresponding host cell receptors important for sporozoite-Kupffer cell interaction in the mammalian liver. Using a similar approach, we identified the HP1 peptide, a structural mimic of a ligand that the sporozoite uses to infect hepatocytes. Immunization with the HP1 peptide protects ~ 50 % mice from P. berghei challenge. Using an anti-HP1 antibody, we identified Plasmodium Phospholipid Scramblase (PLS) as the sporozoite ligand of hepatocytes and a potential vaccine antigen. We propose 1) to identify PLS protein epitopes that function in hepatocyte recognition, for use as a vaccine antigen; and 2) to develop a tri- functional vaccine antigen containing i) a sporozoite circumsporozoite protein (CSP) epitope, targeting liver sinusoid binding, ii) a sporozoite GAPDH-related epitope, targeting sporozoite exit from the circulation via Kupffer cell traversal, and iii) sporozoite PLS epitope, targeting hepatocyte infection. We expect that this approach will lead to enhancement of the moderate protective efficacy of the most advanced RTS,S/AS01 malaria vaccine.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $176,875 )
2024	2024	THE CORPORATION OF MERCER UNIVERSITY	1501 MERCER UNIVERSITY DR	MACON	GA	31207	BIBB	USA	Allergy and Infectious Diseases Research	000	3	12/13/2023	NON-COMPETING CONTINUATION	$159,188
2024	2024	THE CORPORATION OF MERCER UNIVERSITY	1501 MERCER UNIVERSITY DR	MACON	GA	31207	BIBB	USA	Allergy and Infectious Diseases Research	001	3	5/16/2024	NON-COMPETING CONTINUATION	$17,687
														Subtotal = $176,875

Issue Date FY: 2023 ( Subtotal = $215,537 )
2023	2023	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	002	1	5/18/2023	NEW	-$221,437
2023	2023	THE CORPORATION OF MERCER UNIVERSITY	1501 MERCER UNIVERSITY DR	MACON	GA	31207	BIBB	USA	Allergy and Infectious Diseases Research	001	2	5/17/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$191,349
2023	2023	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	000	1	1/4/2023	NEW	$245,625
2023	2023	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	003	1	8/29/2023	NEW	$0
														Subtotal = $215,537

Grand Total All Awards = $392,412

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of novel malaria pre-erythrocytic vaccine antigens targeting Plasmodium sporozoite liver infection

Award Number: R21AI166451

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer